BTIG analyst Julian Harrison downgraded CymaBay (CBAY) to Neutral from Buy without a price target following the announcement of its proposed acquisition by Gilead (GILD) for $32.50 per share. The acquisition “makes sense” as the firm sees seladelpar emerging as the preferred PPAR agonist for the treatment of primary biliary cholangitis and is also not aware of any other active PBC programs in Gilead’s pipeline or portfolio of marketed products, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- M & A News: Gilead (NASDAQ:GILD) to Acquire CymaBay
- CymaBay Therapeutics’ Strategic Merger with Gilead Sciences
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay price target raised to $26 from $22 at Oppenheimer
- CymaBay Therapeutics Boosts Director Equity, Announces Officer Changes